Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of Immunity from Single IPV Dose in Nepal
NCT03723837Phase 4Completed
- Sponsor
- Tribhuvan University Teaching Hospital
- Start
- Nov 2018
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of trivalent inactivated polio vaccine in poliomyelitis (2 arms), sponsored by Tribhuvan University Teaching Hospital. Primary endpoint: Proportion of children with detectable immunity against type 2 poliovirus at 5 weeks. Started Nov 2018; status: completed.
02
Drugs
trivalent inactivated polio vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT03723837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723837.